

3 October 2025

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Notice of Annual General Meeting**

**Scancell Holdings plc (AIM: SCLP)**, the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that the Company's Annual Report and Accounts for the year ended 30 April 2025 and Notice of Annual General Meeting ("AGM") will be sent to shareholders shortly.

The Annual Report and Accounts for the year ended 30 April 2025 are available on the Company's website at <https://www.scancell.co.uk/investors/financial-info>, and the Notice of AGM will be made available today at <https://scancell.co.uk/documents-presentations> under the section titled Annual General Meeting.

The AGM will be held at 3.00pm GMT at the offices of Cooley (UK) LLP at 22 Bishopsgate, London, EC2N 4BQ on Thursday 30th October 2025.

After the AGM, Scancell's senior management team will be presenting the final results for the year ended 30 April 2025 followed by a Q&A session, and all shareholders are invited to attend in person.

**-ENDS-**

**Scancell (LSE:SCLP; [www.scancell.co.uk](http://www.scancell.co.uk))** is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with the intention to hold and develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

*For more information please contact:*

**Scancell Holdings plc**  
Phil L'Huillier, CEO

+44 (0) 20 3709 5700

Sath Nirmalanathan, CFO

**Panmure Liberum (Nominated Adviser and Joint Broker)**  
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  
Rupert Dearden (Corporate Broking)

+44 (0) 20 7886 2500

**WG Partners LLP (Joint Broker)**  
David Wilson, Claes Spang

+44 (0) 20 3705 9330

**Investor and media relations**  
Mary-Ann Chang

+44 (0) 20 7483 284853  
[MaryAnnChang@scancell.co.uk](mailto:MaryAnnChang@scancell.co.uk)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAMTBITMTAMBFA